| First Author | Huo Y | Year | 2016 |
| Journal | Cell Rep | Volume | 15 |
| Issue | 10 | Pages | 2089-2096 |
| PubMed ID | 27239038 | Mgi Jnum | J:238098 |
| Mgi Id | MGI:5818103 | Doi | 10.1016/j.celrep.2016.05.011 |
| Citation | Huo Y, et al. (2016) An In Vivo Gain-of-Function Screen Identifies the Williams-Beuren Syndrome Gene GTF2IRD1 as a Mammary Tumor Promoter. Cell Rep 15(10):2089-96 |
| abstractText | The broad implementation of precision medicine in cancer is impeded by the lack of a complete inventory of the genes involved in tumorigenesis. We performed in vivo screening of approximately 1,000 genes that are associated with signaling for positive roles in breast cancer, using lentiviral expression vectors in primary MMTV-ErbB2 mammary tissue. Gain of function of five genes, including RET, GTF2IRD1, ADORA1, LARS2, and DPP8, significantly promoted mammary tumor growth. We further studied one tumor-promoting gene, the transcription factor GTF2IRD1. The mis-regulation of genes downstream of GTF2IRD1, including TbetaR2 and BMPR1b, also individually promoted mammary cancer development, and silencing of TbetaR2 suppressed GTF2IRD1-driven tumor promotion. In addition, GTF2IRD1 is highly expressed in human breast tumors, correlating with high tumor grades and poor prognosis. Our in vivo approach is readily expandable to whole-genome annotation of tumor-promoting genes. |
